TABLE 7

Anti-HBs antibody persistence at year 5 after booster vaccination, as assessed with a chemiluminescence assay (according-to-protocol cohorts for antibody persistence at 60 months after booster vaccination)a

Group and time pointbnc% with anti-HBs antibody levels of ≥10 mIU/ml (95% CI)Anti-HBs antibody GMC (95% CI) (mIU/ml)
Hib-MenC + PHiD-CV
    Postbooster M2412288.5 (81.5–93.6)154.5 (106.8–223.5)
    Postbooster M3611884.7 (77.0–90.7)92.3 (63.8–133.6)
    Postbooster M6012572.8 (64.1–80.4)45.7 (32.2–64.8)
Hib-MenC + 7vCRM
    Postbooster M2411993.3 (87.2–97.1)218.9 (152.4–314.4)
    Postbooster M3611989.9 (83.0–94.7)142.5 (100.3–202.6)
    Postbooster M6012884.4 (76.9–90.2)85.4 (60.4–120.6)
MenC-CRM
    Postbooster M2411892.4 (86.0–96.5)211.1 (147.1–303.1)
    Postbooster M3612086.7 (79.3–92.2)130.8 (91.9–186.2)
    Postbooster M6012282.0 (74.0–88.3)66.7 (47.2–94.1)
MenC-TT
    Postbooster M2413090.8 (84.4–95.1)189.2 (134.2–266.7)
    Postbooster M3612788.2 (81.3–93.2)128.4 (91.3–180.6)
    Postbooster M6012979.8 (71.9–86.4)64.7 (46.4–90.2)
  • a A booster vaccination for HBV was not given in Spain, in accordance with national recommendations. Data shown here include subjects from all countries combined.

  • b Postbooster M24, approximately 24 months after booster vaccination; postbooster M36, approximately 36 months after booster vaccination; postbooster M60, approximately 60 months after booster vaccination.

  • c n, total number of children with available results.